Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at
Wall Stre
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.